GLP-1 receptor agonist
Semaglutide (Ozempic/Wegovy/Rybelsus) is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved for Type 2 diabetes and chronic weight management. It is one of the most prescribed drugs in the world and has generated enormous public discussion about weight loss, metabolic health, and off-label use.
Track public claims and clinical trial progress. Do not publish dosing, sourcing, or treatment instructions. Separate FDA-approved indications from community discussions about off-label and compounded use.
FDA-approved as Ozempic for Type 2 diabetes (2017), Wegovy for chronic weight management (2021), and Rybelsus as an oral formulation for Type 2 diabetes (2019).
STEP 1 Phase 3 trial showed mean weight loss of 14.9% at 68 weeks, published in NEJM (2021).
SELECT cardiovascular outcomes trial demonstrated reduced major adverse cardiovascular events in non-diabetic patients with obesity, published in NEJM (2023).
One of the most prescribed and discussed drugs globally, with extensive social media coverage and emerging discussions about compounded alternatives.
SUSTAIN-6 trial established cardiovascular safety in Type 2 diabetes patients.
Evidence level: Peer reviewed
Sources: New England Journal of Medicine, ClinicalTrials.gov
Cite the NEJM STEP 1 publication. Results are specific to the trial population and dosing protocol.
Evidence level: Peer reviewed
Sources: New England Journal of Medicine, ClinicalTrials.gov
SELECT was a landmark CV outcomes trial. Track any subsequent label expansions based on this data.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration, U.S. Food and Drug Administration
Confirm approval status against FDA records on each review cycle. Track compounded semaglutide regulatory actions.
Evidence level: Community discussion
Sources: YouTube — Vox, YouTube — Institute of Human Anatomy, YouTube — 60 Minutes
Track media claims that may exceed clinical evidence. Separate approved indications from speculative behavioral and addiction claims.
Source records are stored in the repo and linked from each claim.
Phase 3 trial showing semaglutide 2.4 mg weekly achieved mean weight loss of 14.9% at 68 weeks.
Cardiovascular outcomes trial showing semaglutide reduced major adverse CV events in non-diabetic patients with obesity.
Pre-specified CV outcomes trial establishing cardiovascular safety of semaglutide in Type 2 diabetes.
ClinicalTrials.gov registry for STEP 1, the pivotal semaglutide obesity trial.
ClinicalTrials.gov registry for the SELECT cardiovascular outcomes trial of semaglutide.
ClinicalTrials.gov registry for SUSTAIN-6, establishing CV safety of semaglutide in Type 2 diabetes.
FDA approval of Ozempic (semaglutide) injection for Type 2 diabetes, NDA 209637.
FDA approval of Wegovy (semaglutide 2.4 mg) injection for chronic weight management, NDA 215256.
High-view (3.5M+) Vox explainer on Ozempic/semaglutide. Tracked as major media signal for public claims.
High-view (2.9M+) anatomy-focused explainer. Tracked for physiological claims about GLP-1 drugs.
Mainstream media coverage of Wegovy/Ozempic. Tracked for regulatory and clinical claims in public discourse.
Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon receptor agonist) developed by Eli Li...
Regulatory watchTirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for Type 2...
Evidence review